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Abstract
Background: The high cost and the long time required to bring drugs into commerce is driving efforts to
repurpose FDA approved drugs—to find new uses for which they weren’t intended, and to thereby reduce the
overall cost of commercialization, and shorten the lag between drug discovery and availability. We report on the
development, testing and application of a promising new approach to repositioning.
Methods: Our approach is based on mining a human functional linkage network for inversely correlated modules
of drug and disease gene targets. The method takes account of multiple information sources, including gene
mutation, gene expression, and functional connectivity and proximity of within module genes.
Results: The method was used to identify candidates for treating breast and prostate cancer. We found that (i) the
recall rate for FDA approved drugs for breast (prostate) cancer is 20/20 (10/11), while the rates for drugs in clinical
trials were 131/154 and 82/106; (ii) the ROC/AUC performance substantially exceeds that of comparable methods;
(iii) preliminary in vitro studies indicate that 5/5 candidates have therapeutic indices superior to that of Doxorubicin
in MCF7 and SUM149 cancer cell lines. We briefly discuss the biological plausibility of the candidates at a molecular
level in the context of the biological processes that they mediate.
Conclusions: Our method appears to offer promise for the identification of multi-targeted drug candidates that
can correct aberrant cellular functions. In particular the computational performance exceeded that of other CMap-
based methods, and in vitro experiments indicate that 5/5 candidates have therapeutic indices superior to that of
Doxorubicin in MCF7 and SUM149 cancer cell lines. The approach has the potential to provide a more efficient
drug discovery pipeline.
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Background
The high cost and the long time required to bring drugs
into commerce [1–3] is driving efforts to repurpose FDA
approved drugs—to find new uses for which they weren’t
intended, and to thereby reduce the overall cost of
commercialization, and shorten the lag between drug
discovery and availability [4]. Among the successes of
this approach are sildenafil, originally developed as a car-
diovascular drug [5] and repositioned to treat erectile
dysfunction; and zidovudine (AZT), originally developed
as an anticancer drug [6], and repositioned for the treat-
ment of HIV. These discoveries, though serendipitous,
motivated more systematic approaches which might
amplify the number of discoveries many-fold.
Systematic approaches generally begin with some form
of computer based screening to generate large numbers
of plausible candidates [7–11]. Many current computa-
tional strategies exploit shared similarities among drugs
or diseases and infer similar therapeutic applications or
drug selections. Drug similarities include chemical st-
ructures [12–14], drug-induced phenotypic side effects
[12, 15], molecular activities [16]. Disease similarities in-
clude phenotypic similarity constructed by identifying
similarity between MeSH terms [17] from OMIM
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database [18]; semantic phenotypic similarity [12]. The
efficacy of the candidates generated by such approaches
would not exceed that of existing drugs since the disease
biomarkers remain the same.
A more general approach searches for disease (Gene Ex-
pression Omnibus, GEO) and drug (CMap) induced tran-
scriptional profiles that are inversely correlated [19–23].
Strong anti correlation between the gene expression pro-
files of an FDA approved drug and those of a disease for
which it was not intended identifies the drug as a candi-
date for repositioning. This procedure, though useful, is
relatively agnostic with respect to the functional relations
between profiles (the ordered lists of perturbed genes). A
drug identified this way is limited in that it is not informed
by cellular function, but simply targets a group of gener-
ally non-interacting differentially expressed genes.
The idea underlying our method, which we refer to as
the method of functional modules (MFM), is to impose
the condition that candidates must affect the same
cellular functions in opposite ways, and to use informa-
tion about DNA as well as RNA. In particular we search
for drugs that strongly perturb sets of genes having the
following properties: (i) they share a strong functional
relationship (ii) they are mutated in the disease state (iii)
their expression is highly perturbed by the disease (iv)
they are within significantly perturbed pathways of dis-
eases. Functional association is based on position in a
human functional linkage network (FLN) [24]—an evi-
dence weighted network that provides a quantitative
measure of the degree of functional association among
any set of human genes. This means the method inte-
grates multiple sources of evidence such as protein-
protein interactions and is not limited to catalogued
functional associations, e.g. KEGG, but uses a general
approach to find functional modules.
We used genome-wide transcriptional data for more
than 3500 compounds provided by LINCS [25] and
identified 519 (410) repositioned drug candidates for
breast (prostate) cancer. We also compared the accur-
acy of our method with that of comparable ap-
proaches [20, 22] (see Results). We applied CMap
datasets and ranked bioactive compounds using differ-
ent methods, then compared the predictability of the
ranked lists of compounds (see Statistical validation).
We then presented evidence that a set of disease mu-
tated genes and their nearest FLN neighbors (muta-
tion associated genes (MAGs), see Methods) provided
more functional insight than a set of differentially
expressed genes in the disease.
In addition to these computational assessments, in vitro
viability tests confirmed that 4 our predicted drug candi-
dates were more efficacious than Doxorubicin–an FDA-
approved drug for breast cancer–against MCF7 and
SUM149 cell lines.
Methods
The method built non-incrementally on the work of Shi-
gemizu et al. [22]. In particular: (i) we took account of
information on mutations (DNA) as opposed to just ex-
pression (RNA); and (ii) we took account of functional
information by using a so-called FLN [24], as explained
below. Specifically, we annotated mutated genes on the
FLN [24], and identified and eliminated all genes that 1)
are not within a specified distance of a mutated gene
(the functional module constraint); 2) have a differential
expression below some threshold (the disease condition
constraint); 3) are not in pathways that distinguish the
cancer/normal phenotype.
An FLN [24] is represented as a network of nodes
(genes/proteins) connected by links whose weights are
proportional to the likelihood that the connected nodes
share common biological functions. We set a threshold
on linkage weight so as to exclude approximately 95 %
of the neighbors of any given node, leaving clusters of
functionally related aberrant genes. We carried out the
procedure twice, once starting with mutated genes and
their first nearest neighbors, and then with mutated
genes and their first and second nearest neighbors.
We considered each drug in turn and identified two
FLN landscapes: one defined by genes that are up-
regulated by the disease and down regulated by the
drugs (Up regulated Cancer gene, Down regulated
Bioactive target gene–UCDB) and, the other defined
by genes that are down regulated by disease and up
regulated by the drug (DCUB). Each landscape was
thus an interconnected set of drug and disease per-
turbed genes. Finally we assigned a score, mutual pre-
dictability (discussed below), which measured the
connectivity within each landscape, which is roughly
speaking the extent to which the drug and disease
genes sets are correlated. The greater the relationship,
the higher the likelihood that the drug is a viable
candidate for repositioning. The methodology is sum-
marized in Fig. 1. The specifics follow.
Data sources
Well-documented mutated genes were downloaded from
the Online Mendelian Inheritance in Man (OMIM)
(http://www.ncbi.nlm.nih.gov/omim) [18]. 40 breast can-
cer and prostate cancer and 69 leukemia well-documented
genes were obtained from OMIM (see Additional file 1).
FLN was downloaded from http://visant.bu.edu/misi/fln/.
Transcript levels
The differentially expressed genes were obtained from
the Illumina HiSeq 2000 RNA Sequencing platform for
108 breast and 51 prostate paired tumor and normal
samples, downloaded from the TCGA portal (http://
cancergenome.nih.gov/). Differential expression data in
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response to leukemia (GSE1159, GSE9476) were ob-
tained from the National Center for Biotechnology In-
formation (NCBI) Gene Expression Omnibus (GEO)
(http://www.ncbi.nlm.nih.gov/geo/). The ranked list of
differentially expressed genes was generated using edgeR
[26] and a t-statistic.
Ranked list of differentially expressed genes in re-
sponse to compounds treated in breast cancer (MCF7
cell line), myelogenous leukemia (HL60 cell line), and
prostate cancer (PC3 cell line) were obtained from con-
nectivity map (CMap) build 02 [20], https://www.broa-
dinstitute.org/cmap) and LINCS (level 4) (http://
www.lincscloud.org/) [20].
Mutation-associated genes (MAG)
The procedure maps to the FLN, known mutated drivers
for the disease of interest, and their first nearest neigh-
bors. It then sets the linkage threshold to 0.2, eliminat-
ing 95 % of the links and leaving gene clusters each of
which is relatively homogeneous functionally. The
remaining genes are further selected by 1) setting a
threshold on transcription level; 2) filtering out the
genes that are not in pathways that distinguish pheno-
type (i.e. cancer from normal–see Pathway enrichment
analysis). As indicated below we were left with relatively
small gene sets at the end of the process. In order to
identify well-correlated drug-disease gene sets, the defi-
nitions of up- and down-regulated genes were not tightly
constrained. In particular, we looped through m sets of
various sizes, ranging from the 1000 most up-regulated
genes, to the top half of the total number of genes in
our universe–which depends on the number of probes
on the chip–in increments of 2,000. A similar procedure
was followed to obtain networks of the most down-
regulated genes.
Networks were obtained for each member of our uni-
verse of bioactive compounds. A drug was ranked in ac-
cord with the intersection between its functional
network and the disease functional network, as de-
scribed below. The procedure was then repeated, by
starting with first and second nearest neighbors. The
final number of MAG ranged from 75 to 1074 for breast
cancer; 15 to 460 for prostate cancer; and 46 to 772 for
leukemia.
Pathway enrichment analysis
We focused on the enrichment of pathways abnormally
perturbed in the disease state compared to the normal
Fig. 1 Analytic workflow. (1) After mapping mutated genes to the FLN, identify the functional neighbors that are up or down regulated (DEG:
differentially expressed genes) and within significantly enriched disease pathways (FDR < 0.05). (2) Map the genes that are down or up regulated
by drug candidates to the FLN (3) Compute the MP score; i.e. the significance of the functional overlap between the drug and disease perturbed
genes (see text). (4) Rank the compounds according to the MP score. (5) Compute the sensitivity and specificity of the ranked list of compounds.
(6) Repeat the process with different groups of MAG and DRG (Drug Response Gene) generated by looping over the parameters (m & k). (7)
Choose the parameter set that has highest sensitivity and specificity. (8) The drug candidates are chosen form the ranked list generated by the
best parameter set. (9) The top ranked drug candidates are chosen for in vitro experimental validation
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state. PWEA [27] (http://zlab.bu.edu/PWEA/down-
load.php) was used to identify significantly perturbed
pathways in the gene expression profiles of breast can-
cer, leukemia and prostate cancer described above.
Drug response genes (DRG)
The top (up-regulated) and bottom (down-regulated) k
most differentially expressed genes in response to bio-
active compounds in disease cell lines were selected as
DRG. We restricted the number of up (down)-regulated
DRG to be within +/− 500 genes of the matched down
(up)-regulated MAG. For example, if 500 up-regulated
MAG are in an FLN cluster, k would from a low of 100
to a high of 1000 in increments of 100.
Library of Integrated Cellular Signatures (LINCS)
LINCS profiles are generated using 3,678 and 4,228 bio-
active compounds for breast cancer and prostate cancer,
respectively, each compound typically applied at 6 differ-
ent concentrations (0.0003-177 μM) and 2 time points
(6 and 24 h). We retained the expression profile of a
compound that produced maximal mutual predictability
score before ranking the compounds. Twenty of the
3678 (11 of 4228) were FDA approved drugs for breast
(prostate) cancer.
Connectivity map
We used CMap datasets for comparing the performance
between our method with others. CMap profiles are gen-
erated using 1251, 1079 and 1182 bioactive compounds
for breast cancer, leukemia and prostate cancer, respect-
ively. Eight of the 1251, 6 of 1079, and 7 of 1182 were
FDA approved drugs for breast cancer, leukemia and
prostate cancer respectively.
Drug and clinical trial information retrieval
We collected data from DrugBank (http://www.drug-
bank.ca/). FDA approved drugs from FDA service:
Drugs@FDA. Clinical trial data were downloaded from
https://clinicaltrials.gov.
Mutual predictability (MP)
We used mutual predictability [4] to score the correl-
ation between mutation associated genes (MAG) and
drug response genes (DRG). In essence, mutual predict-
ability is a measure of the degree to which MAG can be
used as seed genes to predict DRG (predictability M-D),
and vice versa (predictability D-M). The mutual predict-
ability of the two sets measures the extent to which
genes in one set can be used to identify (predict) genes
in the other [24]. A disease drug pair with high mutual
predictability has a strong functional relation; the higher
the score, the stronger the relation.
To quantify the predictability M-D, we use MAG as
seeds, and score and rank each gene connected to a seed





where wij weights the link between gene i and seed j,
and the score is 0 if there is no seed connection.
We obtained the sensitivity and specify variation by
using a series of cutoffs on the ranked list. The number
of true positives is taken to be the number of DRG
above a particular cutoff; the number of true negatives is
the number of non-DRG below the cutoff; the number
of false positives is the number of non-DRG above the
cutoff, and the false negatives are the number of DRG
below the cutoff. AUC scores range from 0 and 1, with
0.5 and 1.0 indicating random and perfect predictive
performance, respectively.
AUCD-M as a measure of predictability D-M is simi-
larly calculated. The mutual predictability between
MAG and DRG is then defined as the geometric mean
of AUCD-M and AUCM-D:






Each bioactive compound is thereby ranked by its mu-
tual predictability score.
A detailed example of MP score computation is shown
in Additional file 2, 2-1 and Additional file 3 Figure S1.
Evaluation of predictability
Statistical validation
We determined the extent to which FDA approved can-
cer drugs were enriched in our ranked list by again cal-
culating an AUC as indicated above. Briefly, focus on a
position t from the top. The ratio of FDA approved
drugs for target disease at or above position t, to total
drugs at or above t is counted as TP; the ratio of non-
FDA approved drugs below t to total drugs below t is
TN. The running index t is varied to produce a ROC,
and the area under the curve (AUC) is used as a meas-
ure of predictability. This is of course a non-normalized
result, but as we now indicate it is used only in a relative
way, to compare different parameter sets.
Parameter optimization
Each set of parameters (rank cutoffs m & k for filtering
MAG and selecting DRG) generated different ranked
lists of bioactive compounds. We computed the AUC
score using the ranked list, and chose the best set of
parameters based on the maximum AUC score. Re-
positioned drug candidates were selected from the
ranked list generated by the best parameter set. After
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optimization, the best parameters (number of MAG and
DRG (MAG/DRG)) are 237/700 (UCDB) and 75/100
(DCUB) for breast cancer; and 333/100 (UCDB) and 46/
100 (DCUB) for prostate cancer.
For the ranked list, the significance of the mutual pre-
dictability scores for each compound was estimated by
randomly selecting a set of n DRG, computing the mu-
tual predictability score given the MAG, repeating the
process 100,000 times to generate a null distribution,
and then estimating the probability that our observation
was obtained by chance. We computed the false discov-
ery rate (FDR) for individual compounds by calculating
the expected number of false positives, given the actual
distribution of mutual predictability scores and the null
distribution.
We assessed the significance of the best AUC score by
randomly selecting from LINCS, 20 out of 3678 drugs
for breast cancer and 11 out of 4228 for prostate cancer
as true positives. For CMap, we randomly selected 8 out
of 1251 drugs for breast cancer; 6 out of 1079 for
leukemia; and 7 out of 1182 for prostate cancer. We
then computed the AUC for each parameter set, re-
peated the process 100,000 times and generated a null
distribution. The p-value was used to estimate FDR for
multiple tests.
Comparison with other methods
We applied the methods (Lamb et al. and Shegemizu et
al.) that used CMap data to breast cancer, leukemia and
prostate cancer and compared them with MFM.
Lamb et al. [20]
We queried the 50 to 500 (in increments of 50) up- and
down-regulated signature genes of breast cancer
(MCF7), leukemia (HL60) and prostate cancer (PC3) on
(https://www.broadinstitute.org/cmap/newQuery?servle-
tAction=querySetup&queryType=quick), and obtained
ranked lists of bioactive compounds. The disease signa-
ture genes (FDR < 0.05) were generated from the same
expression data used for MFM, as described in Tran-
script levels. The total number of compounds and the
corresponding cell lines were the same as those were
used for MFM. Then we followed the same procedure as
that was used for MFM to assess the performance. The
highest AUC score was selected for comparison.
Shegemizu et al. [22]
We used the same expression profiles (GDS2617,
GDS2908 and GDS1439) and parameters (1200 and 1400
for UCDB and DCUB for breast cancer; 700 and 800 for
UCDB and DCUB for leukemia; 5200 and 4200 for UCDB
and DCUB for prostate cancer) reported in the [22] to
generate ranked lists of compounds. Performance was
assessed with the same procedure used for MFM.
Experimental validation
Cell cultures and reagents
Cell lines MCF7, SUM149 and MCF10A were obtained
from ATCC (American Type Culture Collection, Manas-
sas, VA) and maintained as recommended. The growth
medium was supplemented with 10 % fetal bovine serum
(FBS), 50 units/ml of penicillin and streptomycin, and
incubated at 37 °C with 5 % carbon dioxide. Dimethyl
sulfoxide (DMSO), at 0.2 %, was used as the vehicle
control.
MTT assay
Metabolic activity of MCF7, MCF10A and SUM149 cells
treated with vehicle (0.1 % DMSO) or repositioned drug
candidates was assessed with the MTT (3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay.
Cells were placed in 96-well plates and treated for 24 h
with drugs with concentrations ranging from 0–1000 μM,
then assayed for metabolic activity. 10 μl of MTT solution
(10 mg/ml in PBS) was added to each well and incubated
for an additional 3 h. The medium was then replaced with
200 μl of DMSO. Absorbance was determined at 570 nm
(experimental absorbance and 690 nm (background ab-
sorbance) by an ELISA plate reader. The inhibitory effect
of drug candidates was expressed as the relative metabolic
activity (% control) and calculated as shown below. The
relative viability was calculated as relative viability =
(experimental absorbance - background absorbance)/
(absorbance of vehicle controls - background absorbance
of vehicle controls) × 100 %.
Results
We screened repositioned drug candidates by using
mutual predictability [24] to score correlation be-
tween mutation-associated genes up-regulated in dis-
ease samples and genes down-regulated by bioactive
compounds (DCUB), and vice versa (UCDB). Since a
high mutual predictability score indicates strong
functional linkage between sets of disease and drug
related genes, our hypothesis is that candidate drugs
so identified have potential to correct the sets of
disease genes and have therapeutic effect on the
disease.
Identification of repositioned drug candidates for breast
cancer and prostate cancer using LINCS
We performed analysis on the most updated data of
gene expression signatures of bioactive compounds from
LINCS [25]. We evaluated the significance of mutual
predictability score of each compound, and FDRs as ex-
plained under Methods.
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Statistics of significant bioactive compounds
Breast cancer
LINCS includes breast cancer cell line expression in re-
sponse to 3678 compounds. We calculated the mutual
predictability score for each of these, as described in
Method – Mutual Predictability Score. The gene sets
associated with each cancer/compound were assigned
p-values as described in Method – Parameter
optimization, to obtain ranked lists of 2435 DCUB
compounds and 1875 UCDB compounds with FDR <
0.05 (Table 1). Of these 510 were FDA approved drug
candidates for repositioning to breast cancer. The de-
tailed description of candidates is in Additional file 4.
Prostate cancer
LINCS includes prostate cancer cell line expression in
response to 4228 compounds. The gene sets associated
with each cancer/compound were assigned p-values to
obtain ranked lists of 2500 DCUB compounds and 1668
UCDB compounds with FDR < 0.05 (Table 1). Of these
291 were FDA approved drug candidates for reposi-
tioning to prostate cancer (Additional file 4).
Supporting evidence
Sensitivity and specificity
To evaluate the predictability of the ranked drug candi-
dates, ROC curves were generated using 20 FDA breast
cancer drugs and 11 FDA prostate cancer drugs as true
positive. The highest AUC scores were 0.86 (p = 1.0E-6)
and 0.83 (p = 4.5E-5) for breast cancer and prostate can-
cer, respectively. We estimated the significance of the
AUC scores as described in Parameter optimization
session.
Comparisons with computational drug repositioning
methods
We compared the predictability of our method with that
of the computational drug repositioning methods, which
screen drugs based on the anti-correlation between simi-
lar gene and disease signatures, omitting the functional
correlation between genes. In order to compare the per-
formance with Shegimizu et al. [22], and CMap [20], we
obtained the expression data of 1251, 1079 and 1182
compounds treated in MCF7, HL60 and PC3 from
CMap data sets. We used methods to generate ranked
drug lists and compared the highest AUC scores. As
shown in Fig. 2 MFM consistently outperforms the 2
pervious methods, sometimes by wide margins.
Recall rate
Among 2587 bioactive compounds with FDR less than
0.05, 20/20 (p = 2.5E-4) FDA breast cancer drugs and 150/
173 (p = 3.1E-10) clinical drugs (compounds that have
been in clinical trials for breast cancer, Additional file 5)
were recalled. For prostate cancer, among 1668 bioactive
compounds with FDR less than 0.05, 10/11 (p = 2.6E-2)
FDA prostate cancer drugs and 89/113 (p = 6.3E-6) clin-
ical drugs were recalled. Significance was calculated using
the Fisher exact test.
Functional plausibility
Breast cancer
One way to characterize the functional implications of
breast cancer MAGs is by estimating the chance prob-
ability of their observed distribution over KEGG path-
ways. We took the MAGs (MAG-UP, see, Additional file
6) that produced the drug ranked lists with the highest
AUC scores after optimization. The MAGs contain 40
breast cancer mutations and their 237 filtered first
Table 1 Breast cancer and prostate cancer repositioned drug candidates identified from analysis of LINCS. Complete lists of
repositioned drug candidates for breast cancer and prostate cancer are shown in Additional file 13
Breast Cancer Prostate Cancer
Total compounds 3678 4228
Compounds that are FDA drugs 632 676
Compounds that are FDA drugs for target disease 20 11
Compounds that are in clinical trial for target disease 154 106
UCDB DCUB UCDB DCUB
Compounds with FDR < 0.05 2435 1875 2500 1668
Compounds that are clinical drugs with FDR < 0.05 (p-value) 131 (6.2E-8) 109 (2.7E-7) 82 (4.9E-5) 67 (4.8E-7)
FDA drugs with FDR < 0.05 427 325 456 317
FDA drugs with FDR < 0.05 in both UCDB and DCUB 244 291
FDA drugs for target disease with FDR < 0.05 (p-value) 20 (2.5E-4) 19 (2.7E-5) 10 (2.6E-2) 9 (5.3E-3)
AUC (p-value) 0.86 (<1.0E-6) 0.81 (<1.0E-6) 0.77 (9E-3) 0.83 (4.7E-5)
Number of MAG/DRG 237/700 75/100 333/100 46/100
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nearest neighbors on the FLN, which are up regulated in
breast cancer (see Additional file 6).
As shown in Additional file 6, we found 95 pathways
over-represented in breast cancer (FDR < 0.05), 18 of
which are classified in KEGG as cancer pathways (22 of
the 287 KEGG pathways, are labeled cancer-related). For
example, [28] found that the spliceosome assembly path-
way is enriched in genes that are overexpressed in breast
cancer samples, compared to benign lesions. They have
shown that siRNA-mediated depletion of SmE (SNRPE)
or SmD1 (SNRPD1) led to a marked reduction of cell
viability in breast cancer cell lines, whereas it had little
effect on the survival of the nonmalignant MCF10A
breast epithelial cells [29].
In addition, signaling pathways that regulate pluripo-
tent stems cells are enriched in overexpressed genes that
are in the functional neighborhood of genes mutated in
breast cancer tissue (MAGs, p = 4E-09). The deregula-
tion of these pathways many play a role in the develop-
ment of chemoresistance of cancer stem cells, including
breast cancer [30]. Other published breast cancer causal
pathways such as Estrogen signaling [31], ErbB [32],
neurotrophin [33], MAPK [34] and PI3K/AKT [35] were
significantly enriched in mutation associated genes
(MAGs).
Prostate cancer
A similar approach was followed for prostate cancer.
As summarized in Additional file 6, we found 117
enriched pathways (FDR <0.05), 18 of which are
KEGG cancer pathways, including the prostate cancer
pathway (p = 6.9E-10). There was also supporting
evidence that showed deregulation of the enriched path-
ways in prostate cancer. For example, T cell infiltration of
the prostate induced by androgen withdrawal has been
found in patients with prostate cancer [36]; the androgen-
androgen receptor (AR) system plays vital roles in prostate
cancer development and progression [37]. Insulin-like
growth factor 1 or insulin signaling has been found
to activate androgen signaling through direct interac-
tions of Foxo1 with androgen receptors. Intervention
of IGF1/insulin-phosphatidylinositol 3-kinase-Akt sig-
naling was reported to be of clinical value for pros-
tate cancer. T cell receptor, PI3K-Akt, FoxO, and
insulin signaling pathways were highly ranked candi-
dates with p < E-05.
A number of studies have shown that breast and pros-
tate cancer are genetically related [38, 39], as are almost
all cancers to various degrees. Our finding that breast
and prostate cancer share 80 pathways is a striking illus-
tration of this connection (see Additional file 6). We ex-
pect that the selected drug candidates having a strong
functional relation (mutual predictability score) with this
set of genes could potentially correct these aberrant
functions.
MFM provides functional insight
We compared the functional information gained from
MAGs with information obtained using disease differen-
tially expressed genes (DEGs) (often referred to as dis-
ease signature genes) exclusively [19, 20]. As shown in
Additional file 6, we found that our current method
identifies more significantly enriched pathways and well-
documented breast cancer and prostate cancer pathways
Fig. 2 Comparison of performance for the MFM with other methods. We applied CMap datasets to compare performance of MFM with
Shegemizu et al. and Lamb et al. The sensitivity and specificity were calculated as explained in the Methods section, and the area under the ROC
curve was used as a measure of performance. UCDB: prediction of drug candidates that can down-regulate genes up-regulated in cancer. DCUB:
prediction of drug candidates that can up-regulate genes down-regulated in cancer. It shows that MFM consistently outperforms the two
methods in different datasets and diseases
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than does the use of differential expression alone. To
make a comparison, we mapped DEGs onto KEGG path-
ways. For breast cancer, one set contains the most up-
regulated 247 DEGs; for prostate cancer, there were 333
up-regulated DEGs. The disease DEGs were generated
from the expression data as explained in Transcript
Level. These results taken collectively suggest that the
inclusion of mutational and functional information into
disease gene signatures, substantially improves prediction
of disease mechanism and adds specificity and accuracy
to the identification of repositioned candidates.
Experimental validation
Repositioned drug candidates inhibit metabolism of breast
cancer cells
We employed an MTT assay to assess cancer cell viabil-
ity after treatments of 5 repositioned drug candidates
(Table 2) [40]. In particular, we tested the viability of 2
breast cancer cell lines: MCF7 (Luminal A subtype), and
SUM 149 (Triple negative, inflammatory breast cancer
subtype). We assessed non specific drug toxicity by com-
paring the inhibition with that obtained against the im-
mortalized but non-malignant MCF10A cell line.
As shown in Additional file 7: Figure S2, Additional
file 8: Figure S3, Additional file 9: Figure S4, Additional
file 10: Figure S5, Additional file 11: Figure S6 and
Additional file 12: Figure-S7, MCF7, SUM149 and
MCF10A cells exposed to increasing concentrations of
drugs for 24 h exhibited a dose dependent reduction in
viability. The important measure of efficacy is therapeutic
index (TI), the IC50 of a drug when it targets a non-
tumor cell line, relative to its IC50 when it targets a tumor
cell line. As shown in Fig. 3, the TIs of candidates tested
against MCF7 and SUM149 are all substantially higher
than that of Doxorubicin. In addition, all drug candidates
except for Triprolidine achieved maximum efficacy (Emax)
at lower concentrations than did Doxorubicin.
Discussion
We developed a computational drug screening method
– based on the correlation between functional modules
of genes perturbed by diseases and drugs – that could
potentially accelerate the introduction of new therapeu-
tics for serious diseases and conditions. Our approach
performed substantially better than previous methods by
computational measures, and successfully predicted
novel drugs that had higher inhibitory effect against
breast cancer in vitro than Doxorubicin. The study bene-
fited substantially from LINCS, the most up to date drug
response expression data sets currently available.
A number of computational drug-repositioning methods
that utilized CMap have been devised and the efficacy of
identified drugs have been supported by in vivo [16, 19] ex-
periments. However, the methodologies are exclusively
based on gene expression, without taking disease driver/
mutated genes or functional information between genes
into account. Sirota, M., et al. [15] searched for drug candi-
dates based on similarities between drug response gene sig-
natures (DEG) and [12] predicted drug molecular functions
based on drug response gene signatures.
Here we indicate a method that has taken this into ac-
count and shows better performance than previous
methods that utilized solely DEGs. We also showed that
there was more functional information gained from
MAGs than significantly differentially expressed genes
(DEGs). Therefore, we believe that the method could
screen more effective therapeutics than previous methods.
Of the five drugs for which we did preliminary in vitro
tests, they all have higher TI in both cell types than does
Doxorubicin. Mefloquine is a lipophilic molecule that is
an FDA-approved anti-malaria agent. It has 3 known
protein targets: Fe(II)-protoporphyrin IX, hemoglobin
subunit alpha, and A2A adenosine receptor (A2AR). Its
antimalarial action is believed to result from inhibition
of heme polymerization within the food vacuole in the
blood stages of the malaria life cycle [41]. Its potential
role as a cancer therapeutic; however, stems from its an-
tagonistic action on A2AR [42].
A study has shown that antagonizing A2AR could pro-
vide a basis for cancer immunotherapy [43]. Preclinical
studies have confirmed that blockade of A2a receptor
activation has the ability to markedly enhance anti-
tumor immunity and be effective against melanoma and
lymphoma [44–46].
Tumors may evade immune repose by usurping
pathways; such as adenosinergic signaling pathway,
that negatively regulates immune response. Tumors
and its microenvironment have been found to have
high levels of adenosine and ATP, which is triggered
by increased cellular turnover and hypoxia [43]. The
extracellular adenosine then activates specific puriner-
gic receptors such as A2AR. The activation of A2AR
in cancer results in inhibition of the immune re-
sponse to tumors via suppression of T regulatory cell
function and inhibition of natural killer cell cytotox-
icity and tumor-specific CD4+ and CD8+ T cell activity,
therefore, inhibition of A2AR by specific antagonists may
enhance anti-tumor immunity.
Table 2 aMutual predicatbility score of breast cancer drug
candiates predicted by MFM
FDA Drug aMP score P-value FDR
Clotrimazole 0.7 5.00E-06 4.88E-05
Triprolidine 0.69 2.00E-05 1.64E-04
Thioridazine 0.69 2.00E-05 1.64E-04
Mefloquine 0.69 3.00E-05 2.28E-04
Fluphenazine 0.66 1.11E-02 2.13E-02
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Immunosuppression is associated with hypoxia and ac-
celerated cell turn over. In accordance with the findings,
in our analysis of pathway enrichment of MAGs for
breast cancer, cell cycle, HIF1 and T cell signaling path-
ways were significantly dysregulated in breast cancer.
Therefore, Mefloquine, the A2aR antagonist could be
applied as an effective immunotherapeutic strategy.
Fluphenazine and Thioridazine are both antipsy-
chotics. The mechanism of action of fluphenazine is not
well established, but it is known to antagonize dopamine
by binding to the D2 receptor. Thioridazine binds a
range of receptor types including dopamine and various
serotonin receptor subtypes. The relationship to inhib-
ition of transformed (MCF7 and SUM149) cells is not
entirely obvious.
In our in vitro study, breast cancer cells (MCF7,
SUM149 and MCF10A) had shown resistance against
Doxorubicin. The Emax of Doxorubcin was higher than
4 out of 5 of our candidate drugs, which corresponds
with the reported fact that breast cancer patients show
drug resistance against Doxorubicin. It also suggests the
ability of our drug candidate to overcome the drug re-
sistance. The study [47] has found that Thioridazine an-
tagonized dopamine receptors, which are expressed on
cancer stem cells (CSC) and breast cancer cells, and
could induce death of leukemia cancer stem cells prefer-
entially without harming normal blood stem cells. The
dopamine receptor pathway is known to regulate the
growth of CSCs [48]. Therefore, Fluphnazine and Thiori-
dazine could inhibit drug resistance of breast cancers by
modulating CSC through dopamine receptor signaling
pathway.
Conclusion
MFM, which utilizes a functional-linkage network, known
mutations, and altered RNA levels, appears to be a prom-
ising method for identifying multi-targeted drug candi-
dates that can correct aberrant cellular functions. In
particular the computational performance exceeded that
of other CMap-based methods, and in vitro experiments
indicate that 5/5 candidates have therapeutic indices su-
perior to that of Doxorubicin in MCF7 and SUM149 can-
cer cell lines. This new approach has the potential to
provide a more efficient drug discovery pipeline.
Additional files
Additional file 1: is a table listing well-documented mutated genes for
breast cancer, prostate cancer and leukemia. (XLS 889 kb)
Additional file 2: and 2–1 show detailed process of MP score
computation. (DOCX 106 kb)
Additional file 3: Figure S1. An example of mutual predictability score
computation. For ROC curve M-D (sensitivity plotted against 1-specificity),
sensitivity and 1 – specificity are defined as follows: sensitivity = TP / (TP +
Fig. 3 a FDA approved indications of predicted drug candidates; b Half maximal inhibitory concentration (IC50) (μM) of predicted drug
candidates and Doxorubicin against MCF7, SUM149 and MCF10A; c and d Therapeutic index (TI) and maximal inhibitory concentrations (Emax) of
predicted repositioned drug candidates on MCF7, SUM149 and MCF10A. (*Currently used FDA drug for breast cancer; Therapeutic index (TI) was
calculated as a ratio of the IC50 of MCF10A, to the IC50 of MCF7 and SUM149)
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FN), 1 - specificity = FP / (TN + FP), where TP is the number of DRG genes
above a particular Si cutoff, TN is the number of genes associated with
neither disease below the cutoff, FP is the number of genes associated with
neither disease above the cutoff, and FN is the number of DRG genes below
the cutoff. ROC curve D-M was plotted in the same way. The MP score
(0.73) is defined as the geometric mean of area under the ROC M-D and
ROC D-M curves: AUC M-D (0.81) and AUCD-M (0.65). (PPTX 299 kb)
Additional file 4: shows detailed description of identified drug
candidates for breast and prostate cancer. (XLSX 140 kb)
Additional file 5: lists FDA-approved and clinical drugs for breast and
prostate cancer. (XLSX 52 kb)
Additional file 6: is a table listing MAGs for breast cancer and prostate
cancer, also has the listing enriched KEGG pathways in breast cancer and
prostate cancer. (XLSX 46 kb)
Additional file 7: Figure S2. Titration curves of cell viability under
treatment of Doxorubicin. Viability of MCF10A, MCF7 and SUM 149 cells
exposed to Doxorubicin with concentrations ranging from 0.5 μM to 200
μM after 24 h incubation. The relative viability was calculated as relative
viability = (experimental absorbance - background absorbance)/
(absorbance of untreated controls - background absorbance of untreated
controls) × 100 % (means ± SD, n = 6). (PPTX 53 kb)
Additional file 8: Figure S3. Titration curves of cell viability under
treatment of Mefloquine. Viability of MCF10A, MCF7 and SUM 149 cells
exposed to Mefloquine with concentrations ranging from 3.125 μM to
100 μM after 24 h incubation. The relative viability was calculated as
relative viability = (experimental absorbance - background absorbance)/
(absorbance of untreated controls - background absorbance of untreated
controls) × 100 % (means ± SD, n = 3). (PPTX 53 kb)
Additional file 9: Figure S4. Titration curves of cell viability under
treatment of Clotrimazole. Viability of MCF10A, MCF7 and SUM 149 cells
exposed to Clotrimazole with concentrations ranging from 3.125 μM to
100 μM after 24 h incubation. The relative viability was calculated as
relative viability = (experimental absorbance - background absorbance)/
(absorbance of untreated controls - background absorbance of untreated
controls) × 100 % (means ± SD, n = 3). (PPTX 53 kb)
Additional file 10: Figure S5 Titration curves of cell viability under
treatment of Thioridazine. Viability of MCF10A, MCF7 and SUM 149 cells
exposed to Thioridazine with concentrations ranging from 3.125 μM to
100 μM after 24 h incubation. The relative viability was calculated as
relative viability = (experimental absorbance - background absorbance)/
(absorbance of untreated controls - background absorbance of untreated
controls) × 100 % (means ± SD, n = 3). (PPTX 54 kb)
Additional file 11: Figure S6. Titration curves of cell viability under
treatment of Fluphenazine. Viability of MCF10A, MCF7 and SUM 149 cells
exposed to Fluphenazine with concentrations ranging from 3.125 μM to
100 μM after 24 h incubation. The relative viability was calculated as
relative viability = (experimental absorbance - background absorbance)/
(absorbance of untreated controls - background absorbance of untreated
controls) × 100 % (means ± SD, n = 3). (PPTX 55 kb)
Additional file 12: Figure S7. Titration curves of cell viability under
treatment of Triprolidine. Viability of MCF10A, MCF7 and SUM 149 cells
exposed to Triprolidine with concentrations ranging from 31.25 μM to
1000 μM after 24 h incubation. The relative viability was calculated as
relative viability = (experimental absorbance - background absorbance)/
(absorbance of untreated controls - background absorbance of untreated
controls) × 100 % (means ± SD, n = 3). (PPTX 55 kb)
Additional file 13: is a table listing predicted drug candidates for breast
and prostate cancer using LINCS dataset. (XLSX 1152 kb)
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